Paediatric Respiratory Reviews
Volume 10, Issue 4 , Pages 178-185 , December 2009

Aspergillus and the paediatric lung

  • Elpis Hatziagorou

      Affiliations

    • 3rd Department of Paediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece
    • ,
  • Thomas J. Walsh

      Affiliations

    • Immunocompromised Host Section, Paediatric Oncology Branch, National Cancer Institute, Bethesda MD, USA
    • ,
  • John N. Tsanakas

      Affiliations

    • 3rd Department of Paediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece
    • ,
  • Emmanuel Roilides

      Affiliations

    • 3rd Department of Paediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece
    • Immunocompromised Host Section, Paediatric Oncology Branch, National Cancer Institute, Bethesda MD, USA
    • Corresponding Author InformationCorresponding author. Tel.:: +30 2310 892444; Fax: +30 2310 992981.

References 

  1. Panagopoulou P, Filioti J, Petrikkos G, et al. Environmental surveillance of filamentous fungi in three tertiary care hospitals in Greece. J Hosp Infect. 2002;52:185–191
  2. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol. 2005;43(Suppl 1):S207–238
  3. Walsh TJ, Roilides E, Cortez K, Kottilil S, Bailey J, Lyman CA. Control, immunoregulation, and expression of innate pulmonary host defenses against Aspergillus fumigatus. Med Mycol. 2005;43(Suppl 1):S165–172
  4. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest. 2002;121:1988–1999
  5. de Almeida MB, Bussamra MH, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev. 2006;7:67–72
  6. Virnig C, Bush RK. Allergic bronchopulmonary aspergillosis: a US perspective. Curr Opin Pulm Med. 2007;13:67–71
  7. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342:756–762
  8. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2000;16:464–471
  9. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest. 1999;116:639–646
  10. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy. 2005;60:1004–1013
  11. Chauhan B, Santiago L, Hutcheson PS, et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2000;106:723–729
  12. Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006;173:1370–1376
  13. Miller PW, Hamosh A, Macek M, Greenberger PA, MacLean J, Walden SM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996;59:45–51
  14. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110:685–692
  15. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(Suppl 3):S225–264
  16. Maurya V, Gugnani HC, Sarma PU, Madan T, Shah A. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest. 2005;127:1252–1259
  17. Crameri R. Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications. Int Arch Allergy Immunol. 1998;115:99–114
  18. Kurup VP, Banerjee B, Hemmann S, Greenberger PA, Blaser K, Crameri R. Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy. 2000;30:988–993
  19. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111:952–957
  20. Vlahakis NE, Aksamit TR. Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc. 2001;76:930–938
  21. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros. 2005;4:215–220
  22. Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant. 2002;21:1237–1241
  23. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696–709
  24. Butz RO, Zvetina JR, Leininger BJ. Ten-year experience with mycetomas in patients with pulmonary tuberculosis. Chest. 1985;87:356–358
  25. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect. 2001;7(Suppl 2):25–31
  26. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79:250–260
  27. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis. 1999;29:1210–1219
  28. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–1466
  29. Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis. 1994;19(Suppl 1):S33–40
  30. Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1997;16:216–221
  31. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007;166:1099–1117
  32. Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis. 1998;27:437–452
  33. Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol. 2007;127:349–355
  34. Steinbach WJ. Paediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J. 2005;24:358–364
  35. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Paediatrics. 2006;117:e711–716
  36. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus infections in a paediatric hospital: a ten-year review. Pediatr Infect Dis J. 1993;12:673–682
  37. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366
  38. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240–248
  39. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis. 2001;20:77–82
  40. Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr. 2002;161:563–574
  41. Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–169
  42. Liese J, Kloos S, Jendrossek V, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr. 2000;137:687–693
  43. Almyroudis NG, Holland SM, Segal BH. Invasive aspergillosis in primary immunodeficiencies. Med Mycol. 2005;43(Suppl 1):S247–259
  44. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore). 1998;77:345–354
  45. Freeman AF, Kleiner DE, Nadiminti H, et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol. 2007;119:1234–1240
  46. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–379
  47. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol. 2003;33:453–460
  48. Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol. 1993;23:177–180
  49. Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Med Mycol. 2006;44:S199–S205
  50. Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in paediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J. 2007;26:558–564
  51. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100:171–178
  52. Francesconi A, Kasai M, Petraitiene R, et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol. 2006;44:2475–2480
  53. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415
  54. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in paediatric patients with invasive fungal infections. Pediatr Infect Dis J. 1999;18:702–708
  55. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166–2172
  56. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536–4545
  57. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51:812–818
  58. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187:1834–1843
  59. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86:405–414

PII: S1526-0542(09)00052-9

doi: 10.1016/j.prrv.2009.06.006

Paediatric Respiratory Reviews
Volume 10, Issue 4 , Pages 178-185 , December 2009

Article Tools

* Image Usage & Resolution